# BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

> **NCT06123884** · PHASE2,PHASE3 · RECRUITING · sponsor: **Bio-Thera Solutions** · enrollment: 526 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Recombinant humanized anti-PD-1 monoclonal antibody injection
- **DRUG:** Cisplatin
- **DRUG:** Bevacizumab Injection
- **DRUG:** carboplatin
- **DRUG:** Paclitaxel for Injection

## Key facts

- **NCT ID:** NCT06123884
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-13
- **Primary completion:** 2026-09
- **Final completion:** 2027-01
- **Target enrollment:** 526 (ESTIMATED)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06123884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06123884, "BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06123884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*